1 / 11

Constructing a regimen

Constructing a regimen. Session 5. Principles of designing an MDR-TB treatment regimen.

alina
Download Presentation

Constructing a regimen

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Constructing a regimen Session 5

  2. Principles of designing an MDR-TB treatment regimen • Include at least four second-line anti-TB drugs likely to be effective as well as pyrazinamide during the intensive phase. More than four second-line anti-TB drugs is recommended if the effectiveness of some of the drugs is uncertain. • The continuation phase should contain at least three second-line anti-TB drugs (pyrazinamide should also be continued in the continuation phase if extensive lung damage is present). More than three second-line anti-TB drugs is recommended if the effectiveness of some of the drugs is uncertain. • Include a fluoroquinolone—a higher generation fluoroquinolone (levofloxacin or moxifloxacin) is strongly preferred. • Ethambutol can be included but is not counted as a core drug in the regimen. • Consider drug resistance data (of individual or region) and patient treatment history when designing a regimen.

  3. Duration of therapy • The intensive phase should be at least 8 months and at least 4 months past conversion (whichever is longer). • Total duration of treatment should be at least 20 months and at least 18 months past conversion.

  4. Constructing the regimen — Group 1 Include pyrazinamide • Pyrazinamide should be included whenever the strain is susceptible or if susceptibility is unknown. • DST to ethambutol is not very reliable and even if the strain is testing susceptible to ethambutol it should not be counted as a core effective drug against MDR-TB strains. First-line INH (H) RIF (R) EMB (E) PZA (Z)

  5. Constructing the regimen — Group 2 Second-line Include an injectable for the intensive phase • Cross resistance between KM and AMK is considered complete • There is cross resistance of CM with KM and AMK • All injectables must be given IM or IV (not absorbed when given orally) • Streptomycin is considered a first-line drug by the WHO First-line INH (H) RIF (R) EMB (E) PZA (Z) Injectable SM KM AMK CM

  6. Constructing the regimen — Group 3 Second-line Include a fluoroquinolone • Highly effective • Minimal side effects • It is recommended to use a higher generation fluoroquinolone (levofloxacin or moxifloxacin) First-line INH (H) RIF (R) EMB (E) PZA (Z) Injectable Quinolone SM KM AMK CM OFX LFX MFX

  7. Constructing the regimen — Group 4 Second-line Complete the regimen with Group 4 drugs (aiming to have four or five second-line drugs — five if you are worried about second-line resistance) • Side effects are common • ETO/PTO may be the most effective Group 4 drugs • If INH A mutation is responsible for the isoniazid resistance, there may be cross-resistance with ETO/PTO First-line Injectable INH (H) RIF (R) EMB (E) PZA (Z) Quinolone SM KM AMK CM OFX LFX MFX Other 2nd-line ETO or PTO CS PAS

  8. Constructing the regimen — Group 5 First-line Third-line Second-line Group 5 drugs are used in cases of extensive resistance such as XDR-TB • Minimal clinical evidence of efficacy • Use two or three agents from Group 5 when it has been determined that a regimen of at least four effective drugs from Groups 2 to 4 are not available. INH (H) RIF (R) EMB (E) PZA (Z) Injectable Quinolone Other agents SM KM AMK CM OFX LFX MFX Amx/Clv Clofazimine High dose H Linezolid Other 2nd-line ETO or PTO CS PAS

  9. Standardized regimens for communities with little or no second-line anti-TB drug resistance. First-line Third-line Second-line A common standardized regimen when very little resistance to second-line drugs exists in the population is: Z-Km-Lfx-Eto-Cs INH (H) RIF (R) EMB (E) PZA (Z) Injectable Quinolone Other agents SM KM AMK CM OFX LFX MFX Amx/Clv Clofazimine High dose H Linezolid Other 2nd-line ETO/PTO CS PAS

  10. Standardized regimens for communities with little or no second-line anti-TB drug resistance. First-line Third-line Second-line A common standardized regimen when significant amounts of resistance to second-line drugs exists in the population is: Z-Km-Lfx-Eto-Cs-PAS INH (H) RIF (R) EMB (E) PZA (Z) Injectable Quinolone Other agents SM KM AMK CM OFX LFX MFX Amx/Clv Clofazimine High dose H Linezolid Other 2nd-line ETO/PTO CS PAS

  11. Adjusting standardized regimens Standardized therapies need to be adjusted in: • Pregnancy • Liver disease • Chronic kidney disease • MDR-TB contacts • History of treatment with second-line drugs

More Related